(株)Veritas In Silico
(株)Veritas In Silico
2026/07/27 Updated
Market Cap:
$16.4M (¥2.7B)
Stock Price:
$2.52 (¥413)
Exchange Rate: 1 USD = ¥163.67
Stock Price Chart
2026/07/27 Updated0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
1.50
PBR (Price to Book Ratio)
vs Industry Avg: +0.2
0.00%
Dividend Yield
vs Industry Avg: -2.95%
Price Trend
2026/07/27 UpdatedShort-term
5-Day MA
-0.39%
Near-term
25-Day MA
-2.55%
Mid-term
75-Day MA
-5.05%
Long-term
200-Day MA
-15.19%
Price & Trading Details
2026/07/27 UpdatedPRICE
Previous Close
¥417
Open
¥413
High
¥416
Low
¥413
Close
¥413
TRADING
Volume
5,000
Average Volume
15,186
Turnover
¥2,065,000
Min. Purchase
¥41,300
Shareholder Composition
Updated 2026/07/0150.2%
Insider Holdings
14.2%
Institutional
35.6%
Public Float
3
Institutional Holders
Insider Holdings
50.2%
Institutional
14.2%
Public Float
35.6%
Financial Performance
2026/07/26 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥179M | ¥360M | ¥195M | ¥91M |
| Gross Profit | - | - | - | - |
| Operating Income | -¥139M | ¥38M | -¥213M | -¥397M |
| Pretax Income | -¥139M | ¥38M | -¥213M | -¥397M |
| Net Income | -¥141M | ¥33M | -¥236M | -¥426M |
| EPS | -¥25.70 | ¥6.01 | -¥37.11 | - |
| Operating Margin | -77.69% | 10.44% | -109.35% | -435.32% |
| Balance Sheet | ||||
| Total Assets | ¥1,599M | ¥1,656M | ¥2,249M | ¥1,885M |
| Total Equity | ¥1,543M | ¥1,576M | ¥2,210M | ¥1,784M |
| Total Liabilities | ¥56M | ¥80M | ¥39M | ¥101M |
| Cash | ¥1,484M | ¥1,549M | ¥2,173M | ¥1,825M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 96.50% | 95.17% | 98.25% | 94.64% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥149M | ¥69M | -¥218M | -¥299M |
| Investing CF | -¥56M | -¥2M | -¥2,006M | ¥451M |
| Financing CF | - | -¥2M | ¥848M | - |
| Free CF | -¥204M | ¥67M | -¥224M | -¥331M |
| Efficiency | ||||
| ROE | -9.17% | 2.10% | -10.70% | -23.86% |
| ROA | -8.84% | 2.00% | -10.51% | -22.58% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 130A
Latest News (5 items)
Company Information
Japanese Name
(株)Veritas In Silico
Stock Code
130A.T (JPX)
Sector / Industry
Healthcare / Biotechnology
Website
https://www.veritasinsilico.com
Employees
19
About
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has commercialization agreement with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.
Data provided by Yahoo Finance